Adjuvant chemotherapy for breast cancer: An update

Seminars in Oncology

Volumn 28, Issue 4, 2001, Pages 359-376

  Tan, Antoinette R ^a   Swain, Sandra M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; MELPHALAN; PACLITAXEL; TAMOXIFEN; TAXANE DERIVATIVE; THIOTEPA; TRASTUZUMAB;

ALOPECIA; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOMYOPATHY; COGNITIVE DEFECT; DOSE RESPONSE; DRUG EFFICACY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LEUKEMIA; MORTALITY; MUCOSA INFLAMMATION; NEUTROPENIA; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK BENEFIT ANALYSIS; THROMBOEMBOLISM; VOMITING;

EID: 0034892579     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(01)90130-7     Document Type: Article

References (102)

1. Polychemotherapy for early breast cancer: An overview of the randomised trials
2. EBCTCG - Updated results from September 2000 worldwide overview
3. Tamoxifen for early breast cancer: An overview of the randomised trials
4. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Project B-16
5. Tamoxifen (T) versus cyclophosphamide, Adriamycin and 5-FU plus either concurrent or sequential T in postmenopausal, receptor (+), node (+) breast cancer: A Southwest Oncology Group phase III intergroup trial (SWOG-8814, INT-0100)
6. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients
7. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group trial VII
8. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer
9. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: A report of the National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group
10. Is the addition of adjuvant chemotherapy always necessary in node-negative postmenopausal breast cancer patients who receive tamoxifen? First results of IBCSG trial IX
11. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: Meta-analysis of quality-adjusted survival
12. CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: First results of Intergroup trial INT 0102
13. Chemotherapy with or without tamoxifen for patients with ER-negative breast cancer and negative nodes: Results from NSABP B-23
14. Adjuvant therapy for breast cancer
15. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute
16. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer
17. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
18. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
19. Scientific inference and predictions; multiplicities and convincing stories: A case study in breast cancer therapy
20. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project protocol B-15
21. Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAFT with tamoxifen (T) alone
22. Prognostic importance of c-erbB-2 expression in breast cancer
23. The relationship between outcome following adjuvant CMF and the presence of estrogen receptor and C-erbB-2 protein in 277 women with primary breast cancer
24. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells
25. Dose-response effect of adjuvant chemotherapy in breast cancer
26. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer
27. Dose and dose intensity of adjuvant chemotherapy for stage-II, node-positive breast carcinoma
28. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer
29. Results of a randomized trial of adjuvant chemotherapy with FEC 50 vs FEC 100 in high risk node-positive breast cancer patients
30. Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer
31. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22
32. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25
33. Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: Feasibility and efficacy
34. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes: Ten-year results
35. Role of paclitaxel in adjuvant therapy of operable breast cancer: Preliminary results of prospective randomized clinical trial
36. Do women with 4 or more involved axillary nodes need Taxol or just more adjuvant chemotherapy?
37. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
38. Overall survival advantage to simultaneous chemotherapy plus the humanized anti-HER2 monoclonal antibody herceptin in HER2-overexpressing metastatic breast cancer
39. Therapeutic advantage of chemotherapy drugs in combination with Herceptin against human breast cancer cells with HER-2/NEU overexpression
40. Results of two open-label multicentre pilot phase II trials with Herceptin in combination with docetaxel and platinum salts (cis- or carboplatin) as therapy for advanced breast cancer in women over-expressing HER2
41. First-line, non-hormonal, treatment of women with HER2 overexpressing metastatic breast cancer with Herceptin (trastuzumab, humanized anti-HER2 antibody)
42. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement
43. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma
44. Randomized controlled trial of high-dose chemotherapy (HD-CNVp) vs standard dose (CAF) chemotherapy for high-risk, surgically treated, primary breast cancer
45. A prospective, randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes: Preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13
46. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomised trial. Scandinavian Breast Group 9401 study
47. Randomized phase III study of high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin in operable breast cancer with 4 or more axillary lymph nodes
48. High-dose chemotherapy for high-risk primary breast cancer: An on-site review of the Bezwoda study
49. High-dose chemotherapy with peripheral blood progenitor cell transplantation in the adjuvant treatment of breast cancer
50. High-dose chemotherapy for breast cancer
51. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate
52. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial
53. Bisphosphonates as anticancer drugs
54. Reduction in new metastases in breast cancer with adjuvant clodronate treatment
55. Bisphosphonates in the reduction of metastases in breast cancer - Results of the extended follow-up of the first study population
56. Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer
57. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-Year results of a randomized controlled trial
58. Factors influencing prognosis in node-negative breast carcinoma: Analysis of 767 T1NOM0/T2N0M0 patients with long-term follow-up
59. Survival experience in the Breast Cancer Detection Demonstration Project
60. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases
61. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
62. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes
63. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15
64. Acquired Protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate, and 5-fluorouracil
65. Chemotherapy for breast cancer decreases plasma protein C and protein S
66. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer
67. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer
68. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer
69. Early and delayed clinical cardiotoxicity of doxorubicin
70. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients
71. Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer
72. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation
73. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy
74. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma
75. Cognitive function in breast cancer patients receiving adjuvant chemotherapy
76. Cognitive dysfunction following adjuvant treatment of breast cancer: A new dose-limiting toxic effect?
77. Risk of leukemia after chemotherapy and radiation treatment for breast cancer
78. Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) on NSABP B-25: An update
79. Leukemogenic potential of adjuvant chemotherapy for early stage breast cancer - The Eastern Cooperative Oncology Group experience
80. Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer
81. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: The University of Texas M.D. Anderson Cancer Center experience
82. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer
83. Breast cancer in young women: Effect of chemotherapy on ovarian function, fertility, and birth defects
84. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer
85. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients
86. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer
87. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double-blind, placebo-controlled study
88. Effects of chemotherapy-induced castration on serum lipids and apoproteins in premenopausal women with node-positive breast cancer
89. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer
90. The 1998 St. Gallen's consensus conference: An assessment
91. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: A randomized, multinational controlled phase III trial
92. Doxorubicin-containing regimens for the treatment of Stage II breast cancer - The National Surgical Adjuvant Breast and Bowel Project experience
93. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: Final report after a 16-year median follow-up duration
94. Randomized trial of adjuvant chemotherapy for operable breast cancer comparing i.v. CMF to an epirubicin-containing regimen
95. Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: An Eastern Cooperative Oncology Group trial
96. Five-year results of a randomized comparison of cyclophosphamide, doxorubicin (Adriamycin) and fluorouracil (CAF) vs. cyclophosphamide, methotrexate and fluorouracil (CMF) for node-positive breast cancer: A Southeastern Cancer Study Group study
97. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: Results of a randomized trial
98. Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resecrable breast cancer with one to three positive axillary nodes
99. Does everyone with breast cancer need adjuvant therapy?